{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"25.0","value":"9.4"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"25.0","value":"9.4"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"23.2","value":"0.0"},{"groupId":"OG003","lowerLimit":"8.0","upperLimit":"27.7","value":"16.1"},{"groupId":"OG004","lowerLimit":"8.2","upperLimit":"26.7","value":"15.9"},{"groupId":"OG005","lowerLimit":"0.1","upperLimit":"27.3","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"18"}],"units":"Participants"}],"description":"ORR was defined as percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) based on the investigator review from start of treatment until progressive disease (PD) or start of subsequent anti-cancer therapy or cancer-related surgery, whichever was earlier, as per response assessment in neuro-oncology (RANO) criteria for primary brain tumors or response evaluation criteria in solid tumors (RECIST) version (v) 1.1 criteria for all other solid tumors. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must be \\<10 millimeter (mm) in short axis. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. PD was defined as at least a 20% increase in sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since treatment started. In addition, sum must have an absolute increase from nadir of 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with rhabdoid tumors (MRT, RTK, ATRT, and selected tumors with rhabdoid features, including SCCOHT, also known as MRTO) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG000","title":"Rhabdoid Tumors: Cohort 1"},{"description":"Participants with other INI-1-negative tumors or any solid tumor with EZH2 GOF mutation, including EMPNST, EMC, myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG001","title":"Other INI1-negative: Cohort 3"},{"description":"Participants with RMC received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG002","title":"RMC: Cohort 4"},{"description":"Participants with ES received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG003","title":"ES: Cohort 5"},{"description":"Participants with ES undergoing optional tumour biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG004","title":"ES Paired Biopsy: Cohort 6"},{"description":"Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"OG005","title":"Chordoma: Cohort 7"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who received at least 1 dose of tazemetostat.","reportingStatus":"POSTED","timeFrame":"Tumor assessment performed at screening and every 8 weeks beginning at Cycle 3 Day 1, until disease progression or the start of subsequent anti-cancer therapy, whichever occurred first, up to 5.75 years (cycle duration: 28 days)","title":"Cohorts 1, 3, 4, 5, 6 and 7: Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}